712-73-2

Usage

Molecular weight

181.16 g/mol

Structure

A triazole derivative with a 4-fluorophenyl group attached to the triazole ring

Usage

Commonly used in organic synthesis as a building block for the preparation of various bioactive molecules and pharmaceuticals

Aldehyde group

Versatile intermediate for the synthesis of heterocyclic compounds and other complex organic molecules

Potential applications

Medicinal chemistry, drug discovery, modulation of biological targets, and pharmacological properties

Additional uses

Fluorescent probe or labeling agent in chemical biology and bioimaging research

Upstream product

• 50-00-0 formaldehyd 
• 1202942-39-9 2-[(4-fluorophenyl)hydrazono]propanedial dioxime 
• 108-24-7 acetic anhydride 
• 7650-45-5 D-arabino-[2]hexosulose-bis-(4-fluoro-phenylhydrazone) 
• 371-14-2 4-fluorophenylhydrazine 

Downstream Products

• 1202942-46-8 (2-(4-fluorophenyl)-2H-1,2,3-triazole-4-yl)methanol 
• 833-60-3 2-(4-fluorophenyl)-2H-1,2,3-triazole-4-carboxylic acid 

Relevant academic research and scientific papers

IAP BIR domain binding compounds

A compound of Formula 1: (I) or salt thereof, as well as methods of making compounds of Formula 1, methods of using compounds of Formula 1 to treat proliferative disorders such as cancer, and related compounds, composition, and methods.

1-Phenyl-1H- and 2-phenyl-2H-1,2,3-triazol derivatives: Design, synthesis and inhibitory effect on alpha-glycosidases

Due to aging and increasingly overweight in human population, the incidence of non-insulin dependent diabetes mellitus (NIDDM or Type 2 DM) is increasing considerably. Therefore, searching for new α-glycosidase inhibitors (GIs) capable of slowing down carbohydrate assimilation by humans is an important strategy towards control of NIDDM. In this report, we disclose the search for new easily accessible synthetic triazoles as anti-diabetic compounds. Two series of non-glycosid triazoles were synthesized (series A and B) and screened against baker's yeast α-glucosidase (MAL12) and porcine pancreatic α-amylase activity (PPA). Of the 60 compounds tested at 500 μM, were considered hits (≥60% inhibition) six triazoles against MAL12 and three against PPA, with the inhibition reaching up to 99.4% on MAL12 and 88.6% on PPA. The IC50 values were calculated for both enzymes and ranged from 54 to 482 μM for MAL12 and 145 to 282 μM for PPA. These results demonstrated the potential activity of simple and non-glycosidic triazoles as an important novel class of GIs for the development of drugs to treat Type 2 DM.

Synthesis and structure-activity relationships of antitubercular 2-nitroimidazooxazines bearing heterocyclic side chains

Recently described biphenyl analogues of the antituberculosis drug PA-824 displayed improved potencies against M. tuberculosis but were poorly soluble. Heterobiaryl analogues of these, in which the first phenyl ring was replaced with various 5-membered ring heterocycles, were prepared with the aim of identifying potent new candidates with improved aqueous solubility. The compounds were constructed by coupling the chiral 2-nitroimidazooxazine alcohol with various halomethyl-substituted arylheterocycles, by cycloadditions to a propargyl ether derivative of this alcohol, or by Suzuki couplings on haloheterocyclic methyl ether derivatives. The arylheterocyclic compounds were all more hydrophilic than their corresponding biphenyl analogues, and several showed solubility improvements. 1-Methylpyrazole, 1,3-linked-pyrazole, 2,4-linked-triazole, and tetrazole analogues had 3- to 7-fold higher MIC potencies against replicating M. tb than predicted by their lipophilicities. Two pyrazole analogues were >10-fold more efficacious than the parent drug in a mouse model of acute M. tb infection, and one displayed a 2-fold higher solubility. 2009 American Chemical Society.